- Home
- ANAB vs BCX Comparison
ANAB vs BCX Comparison
Compare ANAB & BCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- BCX
- Stock Information
- Founded
- ANAB 2005
- BCX 2011
- Country
- ANAB United States
- BCX United States
- Employees
- ANAB N/A
- BCX N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- BCX Finance/Investors Services
- Sector
- ANAB Health Care
- BCX Finance
- Exchange
- ANAB Nasdaq
- BCX Nasdaq
- Market Cap
- ANAB 759.5M
- BCX 713.9M
- IPO Year
- ANAB 2017
- BCX N/A
- Fundamental
- Price
- ANAB $22.23
- BCX $9.25
- Analyst Decision
- ANAB Buy
- BCX
- Analyst Count
- ANAB 10
- BCX 0
- Target Price
- ANAB $42.25
- BCX N/A
- AVG Volume (30 Days)
- ANAB 559.5K
- BCX 370.6K
- Earning Date
- ANAB 05-05-2025
- BCX 01-01-0001
- Dividend Yield
- ANAB N/A
- BCX 6.99%
- EPS Growth
- ANAB N/A
- BCX N/A
- EPS
- ANAB N/A
- BCX N/A
- Revenue
- ANAB $111,872,000.00
- BCX N/A
- Revenue This Year
- ANAB N/A
- BCX N/A
- Revenue Next Year
- ANAB $9.72
- BCX N/A
- P/E Ratio
- ANAB N/A
- BCX N/A
- Revenue Growth
- ANAB 387.20
- BCX N/A
- 52 Week Low
- ANAB $12.21
- BCX $8.25
- 52 Week High
- ANAB $41.31
- BCX $9.90
- Technical
- Relative Strength Index (RSI)
- ANAB 62.32
- BCX 55.57
- Support Level
- ANAB $20.50
- BCX $9.24
- Resistance Level
- ANAB $22.84
- BCX $9.37
- Average True Range (ATR)
- ANAB 1.28
- BCX 0.11
- MACD
- ANAB 0.12
- BCX -0.00
- Stochastic Oscillator
- ANAB 83.24
- BCX 50.00
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About BCX BlackRock Resources of Beneficial Interest
BlackRock Resources & Commodities Strategy Trust operates as an investment trust. Its investment objective is to seek high current income and current gains, with a secondary objective of capital appreciation. The company invests at least 80% of its total assets in equity securities issued by commodity or natural resources companies, derivatives with exposure to commodity or natural resources companies or investments in securities and derivatives linked to the underlying price movement of commodities or natural resources.